Observational studyEndocrine2026
A real-world experience of active surveillance in Bethesda IV thyroid nodules.
Observational study in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeManagement of Bethesda IV thyroid nodules is challenging due to their indeterminate nature and potential overtreatment. The aim was to evaluate the long-term outcomes of an active surveillance (AS) strategy for Bethesda IV nodules using clinical and ultrasound-based selection criteria in a middle-income setting without access to molecular testing.
methodsRetrospective analysis of a multicenter observational cohort. Patients were enrolled between January 2016 and December 2024. Adults with cytologically confirmed Bethesda IV thyroid nodules < 4 cm, TI-RADS 2-4, and no high-risk clinical or radiologic features were offered AS. Patients with prior head and neck cancer, prior radiation, or suspicious lymphadenopathy were excluded. AS with structured clinical and ultrasound follow-up. Surgery was considered for significant growth (≥ 3 mm), new suspicious features, or by clinical/patient decision.
resultsA total of 184 patients (88.6% women, 52.7% <55 years) were included. At 48 months, 87.6% of nodules remained growth-free and 89.0% had not required surgery. Overall, 36 nodules (19.6%) showed growth; 26 patients (14.1%) underwent surgery. The malignancy rate was 7% for the full cohort and 46% among operated patients. Most malignant tumors were low-risk papillary carcinomas. No variable significantly predicted growth, but initial nodule size was associated with surgery (HR 1.06; 95% CI, 1.00-1.12; P = 0.04).
conclusionsIn this cohort, AS for Bethesda IV nodules demonstrated high stability, low malignancy rates, and low surgical conversion, supporting its feasibility in selected patients. In resource-limited settings, AS guided by clinical and ultrasound criteria may safely reduce unnecessary surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.